## **Chapter 6. Signal Transduction** 

Recommended Article: 【Biology】 [Biology Table of Contents](https://jb243.github.io/pages/1457)

---

**1.** [Overview](#1-overview)

**2.** [Transduction](#2-transduction)

**3.** [**Receptor 1.** G Protein-Coupled Receptors](#3-g-protein-coupled-receptors-gpcr)
 
**4.** [**Receptor 2.** Tyrosine Kinase Receptors](#4-tyrosine-kinase-receptors-receptor-tyrosine-kinase-rtk)
 
**5.** [**Receptor 3.** Serine/Threonine Kinase Receptors](#5-serinethreonine-kinase-receptors)

**6.** [**Receptor 4.** Intracellular Receptors](#6-intracellular-receptors)
 
**7.** [**Receptor 5.** Ion Channel Receptors](#7-ion-channels)

**8.** [**Receptor 6.** Adhesion Receptors](#8-adhesion-receptors)
 
**9.** [**Receptor 7.** Other Receptors](#9-other-receptors)

**10.** [Signal Transduction Enhancers](#10-signal-transduction-enhancers)

**11.** [Signal Transduction Inhibitors](#11-signal-transduction-inhibitors)

---

**a.** [Apoptosis](https://jb243.github.io/pages/1426)

---

<br>

## **1\. Overview**

⑴ Life activities are composed of around [200-300](https://www.cheme.cornell.edu/faculty-directory/matthew-delisa#:~:text=life%20depends%20on%20200-300%20core%20biological%20processes) core biological pathways.

⑵ Process

> ① **Step 1.** Reception

> ② **Step 2.** Transduction: Signal amplification through phosphorylation cascade is a representative process.

> ③ **Step 3.** Response: Reactions in the nucleus are related to genes, while reactions in the cytoplasm are related to proteins.

⑶ Characteristics

> ① Specificity: Ligand specificity

> ② Integration

> ③ Amplification: Reaction amplification

> ④ Sensitivity attenuation and adaptation

> ⑤ Communication

⑷ Epistasis

> ① Epistasis in signal transduction: The signal that acts last is considered to have higher epistasis.

> ② [Epistasis in genetics](https://jb243.github.io/pages/72#4-non-memdel-genetics): The gene that acts first is considered to have higher epistasis.

<br>

<br>

## **2\. Transduction**

⑴ Overview

> ① **Case 1.** When the signal attaches to Ser or Thr of a signaling protein: Possible due to the presence of -OH group.

>> ○ Src

>> ○ FAK

>> ○ JAK

>> ○ PTP

>> ○ STP

> ② **Case 2.** When the signal attaches to Tyr of a signaling protein: Possible due to the presence of -OH group.

>> ○ **Case 1** and **Case 2** do not occur simultaneously.

> ③ **Case 3.** CheA

>> ○ Histidine kinase

>> ○ Not involved in serine/threonine pathways.

⑵ **Type 1.** MAPK (Mitogen-Activated Protein Kinases)

> ① Overview

>> ○ Common principle: MAPKKK → MAPKK → MAPK

>> ○ Located near the nucleus.

> ② **1-1.** ERK1/2 (Extracellular Signal-Regulated Kinase) Module: Mammalian MAPK cascade

>> ○ 1<sup>st</sup>. Growth factors, mitogens

>> ○ 2<sup>nd</sup>. MAPKKK stage: A-Raf, B-Raf, C-Raf

>> ○ 3<sup>rd</sup>. MAPKK stage: MKK1/2

>> ○ 4<sup>th</sup>. MAPK stage: ERK1 (MAPK3), ERK2 (MAPK1)

>> ○ 5<sup>th</sup>. Proliferation, differentiation, division

> ③ **1-2.** JNK (c-Jun N-terminal kinase) / p38 Module: Mammalian MAPK cascade

>> ○ 1<sup>st</sup>. Stress stimuli

>> ○ 2<sup>nd</sup>. MAPKKK stage: MEKK1/4, ASK1/2, MLK1/2/3

>> ○ 3<sup>rd</sup>. MAPKK stage: MKK3/6, MKK4, MKK7

>> ○ 4<sup>th</sup>. MAPK stage: p38α/β/γ/δ, JNK1/2/3

>> ○ 5<sup>th</sup>. Cellular apoptosis, inflammatory response, cell differentiation, cell cycle arrest

> ④ **1-3.** ERK5 Module: Mammalian MAPK cascade

>> ○ 1<sup>st</sup>. Morphological stimuli

>> ○ 2<sup>nd</sup>. MAPKKK stage: MEKK2/3

>> ○ 3<sup>rd</sup>. MAPKK stage: MKK5

>> ○ 4<sup>th</sup>. MAPK stage: ERK5

>> ○ 5<sup>th</sup>. Formation of endothelial cell lumen

> ⑤ **1-4.** Yeast MAPK cascade

>> ○ α-factor pheromone → Ste11 → Ste7 → Fus3 → Cell cycle arrest, mating

>> ○ Starvation → Ste11 → Ste7 → Kss1 → Filament elongation

>> ○ Hyperosmotic stress → Ssk2/22 → Pbs2 → Hog1 → Glycerol synthesis

>> ○ Hypoosmotic stress → Bck1 → MKK1/2 → Mpk1 → Cell wall remodeling

>> ○ Nutrient deprivation → Cak1 → Smk1 → Meiosis, Spore formation

 ⑶ **Type 2.** CDK (Cyclin-Dependent Kinase)

> ① Function: [Regulation of cell cycle](https://jb243.github.io/pages/71#2-vertical-transfer-of-genes-cell-division)

> ② Types and related regulators

>> ○ Cyclin A, B, D, E

>> ○ CDK 1, 2, 4, 6

>> ○ MPF, CDC, CDI, APC

>> ○ Myc

>> ○ p53, p21, mdm

>> ○ Bax, cytochrome C, Caspase

>> ○ Rb, E2F

>> ○ WEE1, CDC25

⑷ **Type 3.** NF-κB pathway

> ① 1<sup>st</sup>. NF-κB forms a complex with Iκ-B protein in the cytoplasm under normal conditions.

>> ○ Iκ-B inhibits the movement of NF-κB to the nucleus.

> ② 2<sup>nd</sup>. Signal molecules like TNF-α trimer bind to receptors.

> ③ 3<sup>rd</sup>. IKK (inhibitor kappa kinase) is activated.

> ④ 4<sup>th</sup>. Serine-threonine kinase RIP is activated.

> ⑤ 5<sup>th</sup>. Iκ-B is activated and degraded in the cytoplasm.

> ⑥ 6<sup>th</sup>. NF-κB is dissociated from Iκ-B and moves to the nucleus.

> ⑦ 7<sup>th</sup>. NF-κB produces proteins related to macrophage inflammation.

>> ○ Macrophages have pro-inflammatory M1 and anti-inflammatory M2 types.

>> ○ NF-κB helps macrophages transition to the M1 type.

 ⑸ **Type 4.** mTOR (Mammalian Target of Rapamycin)

> ① Serine/threonine kinases evolutionarily conserved from yeast.

> ② Inhibited by rapamycin.

> ③ PI3K → Akt → mTOR → Cell division, cell proliferation, cell survival, angiogenesis, nutrient uptake, energy production

 ⑹ **Type 5.** GSK3

 ⑺ **Type 6.** CLK

<br>

<br>

## **3\. G Protein-Coupled Receptors (GPCR)**

⑴ Overview

> ① GPCRs are the target of approximately 40% of prescription drugs.

> ② Overall structure diagram

<br>

![image](https://github.com/user-attachments/assets/7ec023e0-423e-4f0e-a902-650b0f0fe7f0)

**Figure 1.** Structure of G Protein-Coupled Receptors 

<br>

⑵ **Component 1.** Membrane Receptors (GPCR)

> ① The most diverse type of cell membrane receptor.

> ② Structure: Penetrates the cell membrane 7 times (7TM, 7 trans-membrane). In other words, there are 7 α-helices.

> ③ The G-protein is attached between the 5th and 6th transmembrane domains.

⑶ **Component 2.** G Protein

> ① Location: Attached between the 5th and 6th transmembrane domains of the GPCR, exposed to the cytoplasm.

> ② Function: Converts GTP to GDP.

>> ○ Activates enzymes that generate 2nd messengers after being activated by GPCRs, contributing to signal transduction.

>> ○ Binds with GTP for activation, and with GDP for inactivation.

>> ○ Activates 2nd messengers like PKA, PKC, PKG.

>> ○ Opens (e.g., olfaction) or closes ion channels.

>> ○ There's a connection between directly opening ion channels and sensitivity to olfaction.

> ③ Structure: Composed of three subunits of Gα, Gβ, Gγ.

>> ○ Gβ and Gγ subunits are always together.

>> ○ When triggered by GPCR, the GDP bound to the αβγ complex is released, leading to the separation of the α subunit and the βγ complex, thereby activating the G-protein.

>> ○ The βγ complex activates adenylyl cyclase (AC) and phospholipase C (PLC).

> ④ Various types of α subunits exist as follows.

> ⑤ **Type 1.** Gα<sub>s</sub> (stimulatory)

>> ○ Activation of adenylyl cyclase (AC): The second messenger is cAMP.

>> ○ 1<sup>st</sup>. G protein moves to GPCR and gets activated.

>> ○ 2<sup>nd</sup>. α<sub>s</sub> subunit of G protein activates adenylyl cyclase (AC).

>> ○ 3<sup>rd</sup>. AC converts ATP to cAMP.

>> ○ 4<sup>th</sup>. cAMP activates PKA, initiating phosphorylation cascade.

>> ○ Examples: β-adrenergic (epinephrine) receptor, glucagon receptor, serotonin receptor, vasopressin receptor

> ⑥ **Type 2.** Gα<sub>i</sub> (inhibitory)

>> ○ Inhibition of adenylyl cyclase (AC): The second messenger is cAMP.

>> K<sup>+</sup> Channel: Activated by G<sub>βγ</sub>. The second messenger is the change in membrane potential.

>> ○ 1<sup>st</sup>. The βγ complex is separated from the α subunit by GPCR.

>> ○ 2<sup>nd</sup>. α<sub>i</sub> subunit inhibits adenylyl cyclase (AC).

>> ○ 3<sup>rd</sup>. Down-signaling occurs.

>> ○ Examples: α<sub>2</sub>-adrenergic receptor, muscarinic acetylcholine receptor

> ⑦ **Type 3.** Gα<sub>q</sub>

>> ○ Activation of PLC (phospholipase C): The second messengers are IP<sub>3</sub> and DAG.

>> ○ 1<sup>st</sup>. When a signaling molecule binds to a G-protein-coupled receptor, it activates phospholipase C (PLC).

>> ○ 2<sup>nd</sup>. The inositol phospholipid PIP<sub>2</sub> is hydrolyzed by PLC into DAG (diacylglycerol) and inositol IP<sub>3</sub>.

>> ○ 3<sup>rd</sup>. Both DAG and IP<sub>3</sub> act as secondary messengers, activating different pathways.

>> ○ 4<sup>th</sup>. IP<sub>3</sub> rapidly diffuses into the cytoplasm and acts as a ligand for the IP<sub>3</sub>-gated channels on the smooth endoplasmic reticulum membrane, facilitating the release of Ca<sup>2+</sup> from the smooth endoplasmic reticulum into the cytoplasm.

>> ○ 5<sup>th</sup>. The released calcium binds to calmodulin or acts as a second messenger to activate PKC (phosphokinase C) and other proteins. DAG also participates in activating protein kinases.

>> ○ 6<sup>th</sup>. The α subunit of the G-protein possesses GTPase activity, hydrolyzing GTP to GDP and P<sub>i</sub>, which allows it to terminate signal transduction spontaneously.

>> ○ Example: α<sub>1</sub>-adrenergic receptor

> ⑧ **Type 4.** Gα<sub>t</sub>

>> ○ Activation of cGMP phosphodiesterase: The second messenger is cGMP.

>> ○ Example: Rhodopsin in rod cells.

> ⑨ **Type 5.** Gα<sub>O</sub>

>> ○ Inhibition of adenylyl cyclase (AC): The second messengers are IP<sub>3</sub> and DAG.

>> ○ Example: Acetylcholine receptor in endothelial cells.

> ⑩ **Type 6.** Gα<sub>olf</sub>

>> ○ Activation of adenylyl cyclase (AC): The second messenger is cAMP.

>> ○ Example: Olfactory receptor.

> ⑪ **Type 7.** G<sub>g</sub>

> ⑫ **Type 8.** G<sub>11</sub>

>> ○ Activation of phospholipase C (PLC).

> ⑬ **Type 9.** G<sub>12,13</sub>

⑷ **Component 3.** Small GTPase

> ① Similar function as G proteins but smaller in size: About 1/10 the size of G proteins.

> ② **Example 1.** Rho: Attaches cell membrane receptors to the cytoskeleton, regulating cell shape and movement.

> ③ **Example 2.** Ras (rat sarooma)

>> ○ A GPCR activated by tyrosine kinase, involved in the signal transduction pathway.

>> ○ Plays an important role in activating MAPK.

>> ○ Normal functions: Cell proliferation, cell differentiation, cell survival.

>> ○ Ras is furtherdivided into H-Ras, K-Ras, N-Ras, etc.

>> ○ Ras genes are one of [oncogenes](https://jb243.github.io/pages/71).

> ④ **Example 3.** ARF1, ARF6: Involved in the early formation of the autophagosome.

⑸ **Component 4.** Related regulators

> ① PKA (Phosphokinase A)

>> ○ Serine/threonine kinase activated by cAMP.

>> ○ PKA acts on ligase to oxidize fatty acids.

> ② PKC (Phosphokinase C)

>> ○ Kinase activated by DAG.

>> ○ Phosphorylates glycogen synthase, etc.

> ③ PKG (Phosphokinase G)

>> ○ PKG opens K<sup>+</sup> channels and closes Ca<sup>2+</sup> channels.

> ④ cAMP: A secondary messenger

>> ○ There are also G proteins that regulate cAMP.

>> ○ Serotonin can increase cAMP by more than 100 times.

>> ○ Adenylyl cyclase: Converts ATP to cAMP.

>> ○ PDE (phosphodiesterase): Breaks down cAMP.

> ⑤ Adenylyl Cyclase (AC)

>> ○ AC converts ATP to cAMP.

>> ○ cAMP directly activates PKA, a type of Ser/Thr kinase: Mainly in skeletal muscles.

>> ○ When the signal from AC disappears, cAMP is converted to AMP by a phosphodiesterase.

>> ○ Gα<sub>s</sub>: Activates adenyl cyclase.

>> ○ Gα<sub>i</sub>: Inhibits adenyl cyclase.

> ⑥ Phospholipase C (PLC)

> ⑦ Calmodulin (CaM): Ca<sup>2+</sup>-binding protein

>> ○ Extracellular Ca<sup>2+</sup> / Intracellular Ca<sup>2+</sup> = 10,000.

>> ○ Found in the cytoplasm of all eukaryotic cells, including plants, fungi, and protists.

>> ○ Binding with Ca<sup>2+</sup> changes its structure, enabling its binding with various intracellular proteins.

>> ○ Particularly, Ca<sup>2+</sup>/calmodulin-dependent kinases (CaM-kinase) activated by calmodulin phosphorylate specific proteins, influencing various cellular responses.

>> ○ Example: NO (Nitric oxide).

> ⑧ PIP<sub>2</sub>: Phosphatidyl inositol 4,5-bisphosphate.

> ⑨ DAG: Diacylglycerol.

> ⑩ IP<sub>3</sub>: Inositol triphosphate.

> ⑪ GAP (GTPase accelerating protein)

>> ○ Assists Gα in GTPase function via Ras.

>> ○ Inactivates G proteins.

> ⑫ GEF (Guanine-nucleotide exchange factor)

>> ○ Catalyzes the binding of Ras and GTP.

>> ○ Assists in the reactivation of G proteins.

>> ○ GDP → GTP (i.e., brings in new GTP).

⑹ **Example 1.** Glycogen breakdown regulation: cAMP.

<br>

![image](https://github.com/user-attachments/assets/21a83f3c-7606-48ff-a4ea-a49846305ee9)

**Figure 2.** Schematic of the adrenaline signaling pathway

<br>

> ① 1<sup>st</sup>. Epinephrine (adrenaline) binds to the epinephrine receptor, a type of GPCR.

> ② 2<sup>nd</sup>. G protein moves to the GPCR and gets activated.

> ③ 3<sup>rd</sup>. α<sub>s</sub> subunit of the G protein activates adenylyl cyclase (AC).

> ④ 4<sup>th</sup>. AC converts ATP to cAMP.

> ⑤ 5<sup>th</sup>. cAMP activates PKA, initiating a phosphorylation cascade.

> ⑥ 6<sup>th</sup>. Phosphorylation cascade eventually activates glycogen phosphorylase, leading to glycogen breakdown.

> ⑦ 7<sup>th</sup>. Glucose production.

⑺ **Example 2.** Metabotropic acetylcholine receptor (muscarinic receptor)

> ① Overview

>> ○ Found at the terminal synapses of all postsynaptic nerve fibers in the parasympathetic nervous system.

>> ○ Also found in the brain, heart, and smooth muscles.

>> ○ Present in GPCR and the sinoatrial node but not in cardiac muscle fibers.

>> ○ Responds to muscarine.

>> ○ **Type 1.** M1, M2, M5: Excitatory receptors

>> ○ **Type 2.** M3, M4: Inhibitory receptors

> ② Mechanism

>> ○ 1<sup>st</sup>. Gα<sub>i</sub> is activated.

>> ○ 2<sup>nd</sup>. When acetylcholine (Ach) binds to muscarinic receptors, the βγ subunit separates from the α subunit.

>> ○ 3<sup>rd</sup>. The α<sub>i</sub> subunit inactivates adenylyl cyclase, acting antagonistically to the Gα<sub>s</sub> protein.

>> ○ 4<sup>th</sup>. The β-γ complex of the G-protein binds to K<sup>+</sup> ion channels, causing K<sup>+</sup> to diffuse out of the cell, leading to a decrease in heart rate.

> ③ Examples

>> ○ **Example 1.** Acetylcholine receptors found in the parasympathetic nervous system.

>> ○ **Example 2.** Primarily found at the junctions between cardiac cells and parasympathetic nerves.

>> ○ **Example 3.** Nitric oxide (NO) and [vascular relaxation model](https://jb243.github.io/pages/88).

> ④ Inhibitors

>> ○ Atropine: Antidote for muscarinic toxins. Stimulates sympathetic nerve activity.

>> ○ Sarin, DIFP, Tabun: Covalent inhibitors of acetylcholinesterase.

 ⑻ **Example 3.** Adrenergic receptor (adrenoceptor)

> ① Binds to catecholamine hormones, norepinephrine, epinephrine, beta-blockers, β<sub>2</sub> agonists, and α<sub>2</sub> agonists.

> ② Adrenergic receptors mainly located in arterioles, with different functions and types based on location.

>> ○ Liver cells: Epinephrine beta receptors → Increase blood glucose.

>> ○ Skeletal muscle blood vessels: Epinephrine beta receptors → Vasodilation.

>> ○ Intestinal blood vessels: Epinephrine alpha receptors → Vasoconstriction.

>> ○ Cardiac muscles and other smooth muscle arterioles: Epinephrine beta receptors → Arteriolar dilation → Increased blood flow → Contraction of cardiac muscles and other smooth muscles.

>> ○ Visceral organ arterioles: Epinephrine alpha receptors → Arteriolar constriction → Decreased blood flow to visceral organs → Visceral muscle relaxation.

> ③ Total of 9 subtypes: α<sub>1A</sub>, α<sub>1B</sub>, α<sub>1D</sub>, α<sub>2A</sub>, α<sub>2B</sub>, α<sub>2C</sub>, β<sub>1</sub>, β<sub>2</sub>, β<sub>3</sub>.

>> ○ α<sub>1</sub> couples with Gα<sub>q</sub> protein. Found in arterioles supplying blood to visceral organs.

>> ○ α<sub>2</sub> couples with Gα<sub>i</sub> protein.

>> ○ All β receptors couple with Gα<sub>s</sub> protein.

>> ○ β<sub>1</sub>: Found exclusively in the heart, distributed in the sinoatrial node and ventricular muscle.

>> ○ β<sub>2</sub>: Supplies blood to the musculoskeletal system and is distributed in arterioles.

>> ○ Both β<sub>2</sub> and β<sub>3</sub> also couple with Gα<sub>i</sub> protein.

 ⑼ **Example 4.** Inhibition of G protein function

> ① Cholera toxin: AB toxin

>> ○ 1<sup>st</sup>. B subunit of AB toxin reacts with GPCR, and A enters the cell.

>> ○ 2<sup>nd</sup>. GPCR activates Gα<sub>s</sub>.

>> ○ 3<sup>rd</sup>. Gα<sub>s</sub> reacts with ADP-ribose, reducing GTPase activity.

>> ○ 4<sup>th</sup>. Reduced GTPase activity increases adenylyl cyclase activity.

>> ○ 5<sup>th</sup>. Adenylyl cyclase generates cAMP from ATP.

>> ○ 6<sup>th</sup>. Increased cAMP activates PKA.

>> ○ 7<sup>th</sup>. ATP binds to the R domain of CFTR channel via PKA, opening the channel.

>> ○ 8<sup>th</sup>. Increased Cl<sup>-</sup> secretion leads to water release through osmosis, causing diarrhea and dehydration.

> ② Pertussis toxin

>> ○ 1<sup>st</sup>. ADP-ribose reacts with G<sub>i/o</sub>, decreasing G<sub>i/o</sub> activity.

>> ○ 2<sup>nd</sup>. Adenylyl cyclase activity increases.

>> ○ 3<sup>rd</sup>. Increased cAMP reduces the secretion of chemotactic substances in infected cells.

>> ○ 4<sup>th</sup>. Diminished immune cell recruitment increases infection and triggers respiratory diseases.

 ⑽ **Example 5.** Other examples of GPCRs.

> ① [Norepinephrine receptor in brown adipose tissue](https://jb243.github.io/pages/81)

> ② [Transduction in rod cells](https://jb243.github.io/pages/1289)

> ③ [Olfactory nerve cells](https://jb243.github.io/pages/1292)

> ④ [Somatostatin receptors](https://jb243.github.io/pages/89): SSTR1 ~ SSTR5

> ⑤ [FSH receptor](https://jb243.github.io/pages/553)

> ⑥ [Slow block mechanisms for polyspermy during sea urchin development](https://jb243.github.io/pages/1448)

<br>

<br>

## **4\. Tyrosine Kinase Receptors** (receptor tyrosine kinase, RTK)

 ⑴ **Component 1.** RTK

> ① TKD: Tyrosine kinase domain

 ⑵ **Component 2.** Related regulators

> ① rho: Attaches cell membrane receptors to the cytoskeleton to regulate cell shape and movement.

> ② Ras (rat sarcoma)

>> ○ A GPCR activated by tyrosine kinase, involved in the signal transduction pathway.

>> ○ Plays an important role in activating MAPK.

>> ○ Normal functions: Cell proliferation, cell differentiation, cell survival.

>> ○ Ras is furtherdivided into H-Ras, K-Ras, N-Ras, etc.

>> ○ Ras genes are one of [oncogenes](https://jb243.github.io/pages/71).

> ③ PI3K(PI3-kinase): Converts PI(4,5)-P2 to PI(3,4,5)P3, allowing PDK1 and Akt to bind.

> ④ JAK-STAT: STAT1,2, SH2 are involved.

> ⑤ MAPK

> ⑥ Src family

> ⑦ FAK

> ⑧ Myc

⑶ Mechanism

> ① 1<sup>st</sup>. Ligand binding: Growth factors bind to receptors.

> ② 2<sup>nd</sup>. Autophosphorylation: Each receptor can phosphorylate itself while transferring phosphate to the opposite tyrosine.

>> ○ Has an ATP binding site, so phosphorylation uses ATP.

> ③ 3<sup>rd</sup>. Mediating proteins like GRB2 bind, facilitating the recruitment of the Sos factor.

>> ○ Sos factor: Acts as a GEF, separating GDP from Ras and binding GTP to activate it.

>> ○ GEF (guanine-nucleotide exchange factor): Aids in G-protein reactivation. GDP → GTP (i.e., brings in new GTP).

> ④ 4<sup>th</sup>. Sos factor activates Ras, and activated Ras activates Raf.

>> ○ Nearly all receptor tyrosine kinases that bind growth factors activate Ras protein.

> ⑤ 5<sup>th</sup>. Raf catalyzes MEK phosphorylation.

>> ○ Raf is a serine/threonine kinase.

> ⑥ 6<sup>th</sup>. MAPK is activated during MEK phosphorylation and then moves into the nucleus.

>> ○ MAPK: Reacts sequentially and is also known as ERK.

>> ○ ERK1/2: Feedback inhibition of GRB2 / SOS.

> ⑦ 7<sup>th</sup>. The previously inactive transcription factor Myc is now activated, leading to the production of Cyclin D.

> ⑧ 8<sup>th</sup>. The above signaling is halted by removing phosphate from phosphorylated sites through tyrosine dephosphorylase.

⑶ Tyrosine kinase inhibitors

> ① Imatinib (Glivec)

> ② Dasatinib (Sprycel)

> ③ Sunitinib (Sutent)

> ④ Nilotinib (Tasigna)

> ⑤ Sorafenib (Nexavar)

> ⑥ Temsirolimus (Torisel)

> ⑦ Nintedanib: Treatment medication for pulmonary fibrosis.

> ⑧ Pirfenidone: Treatment medication for pulmonary fibrosis.

 ⑷ **Example 1.** EGFR (epidermal growth factor receptor)

> ① **Component 1.** EGFR

>> ○ Also known as ErbB1 or HER-1.

>> ○ Structure: 170 kDa glycoprotein

>>> ○ Protein composition: Consists of a single polypeptide made up of 1,186 amino acids.

>>> ○ Initial precursor: Consists of a single polypeptide made up of 1,210 amino acids.

>> ○ 60-80% of colorectal cancers overexpress EGFR.

> ② **Component 2.** EGF

>> ○ Structure: 6 kDa. Human EGF consists of 53 amino acids.

> ③ EGFR Signaling Pathway

>> ○ 1<sup>st</sup>. When EGF and EGFR bind, it causes a change in structure, activating TKD.

>> ○ 2<sup>nd</sup>. The following types of signaling proteins bind to phosphorylated EGFR.

>>> ○ **Type 1.** SH2 (Src homology-2): The N-terminus of SH2 recognizes the sequence of tyrosine.

>>> ○ **Type 2.** PTB (phosphotyrosine binding) domain of Shc: The C-terminus of the PTB domain binds.

>> ○ 3<sup>rd</sup>. Major downstream signaling

>>> ○ Ras → Raf → ERK

>>> ○ PI3K → Akt → mTOR

<br>

![image](https://github.com/user-attachments/assets/2547584f-84bc-4319-8b74-2eeaeb00daed)

**Figure 3.** EGFR signaling pathway

<br>

> ④ Positive feedback regulators

>> ○ ERBB ligands, such as TGFα and HB-EGF, show increased expression following the above signaling pathways.

> ⑤ Negative feedback regulators

>> ○ DEP (density-enhanced phosphatase-1)

>> ○ SOCS5 (cytokine signaling-5)

> ⑥ Inhibitors

>> ○ Gefitinib (Iressa): An anticancer drug that inhibits EGFR-TKI (EGFR-tyrosine kinase inhibitor). FDA-approved.

>> ○ Erlotinib (Tarceva)

>> ○ Cetuximab (Erbitux): FDA-approved.

>>> ○ IgG1 isotype

>>> ○ Binding site: Q384, Q408, H409, K443, K465, I467, S468, F352, D355, P387

>>> ○ Has immunogenic activity.

>> ○ Panitumumab (Vectibix): FDA-approved.

>>> ○ IgG2 isotype

>>> ○ Binding site: P349, P362, D355, F412, I438

>>> ○ No immunogenic activity.

>> ○ Lapatinib (Tyverb): Directly inhibits downstream signaling by inhibiting TKD. FDA-approved.

>> ○ Afatinib: Directly inhibits downstream signaling by inhibiting the tyrosine-kinase domain. FDA-approved.

>> ○ Sapitinib

 ⑸ **Example 2.** HER2 (erbB-2): Also known as CD340, Neu, Erbb2 (rodent), ERBB2 (human).

> ① Structure: (Extracellular) I - II - III - IV - Transmembrane domain - TKD (Intracellular)

>> ○ II: Dimerization domain

> ② Function

>> ○ Overexpression of HER2 leads to excessive cell proliferation through autophosphorylation: Associated with poor prognosis, tumor formation, etc.

>> ○ Overexpressed in 15-40% of ovarian cancer cases.

> ③ Mechanism: Utilizes PI3-kinase signaling

> ④ Positive feedback regulators

>> ○ ERBB2: Once activated, subsequent activation is facilitated.

>> ○ Heterodimer containing ERBB2.

>> ○ ERBB ligands, such as TGFα and HB-EGF, show increased expression following the above signaling pathways.

> ⑤ Inhibitors

>> ○ Pertuzumab: Inhibits II, inhibiting receptor dimerization. FDA-approved.

>> ○ Trastuzumab, margetuximab: Inhibits IV. Associated with ADCC. FDA-approved.

>> ○ Trastuzumab emtansine (T-DM1): Conjugates anticancer drug with trastuzumab. FDA-approved.

>> ○ Trastuzumab deruxtecan: Conjugates anticancer drug with trastuzumab. FDA-approved.

>> ○ Lapatinib: Directly inhibits downstream signaling by inhibiting TKD. FDA-approved.

>> ○ Afatinib: Directly inhibits downstream signaling by inhibiting TKD. FDA-approved.

>> ○ Neratinib: Directly inhibits downstream signaling by inhibiting TKD. FDA-approved.

>> ○ Sapitinib

>> ○ CI-1033

 ⑹ **Example 3.** HER3 (erbB-3)

> ① Inhibitors: Sapitinib

 ⑺ **Example 4.** IGF-1R (insulin-like growth factor receptor)

> ① Structure

>> ○ Extracellular ligand-binding domain: Contains two α subunits.

>> ○ Transmembrane domain

>> ○ Cytoplasmic domain: Contains two β subunits.

>> ○ Total of 3 disulfide bonds: α-α, α-β, α-β

>> ○ β subunits function as tyrosine kinases.

> ② IGF-1R can bind to ligands IGF-1 and IGF-2.

> ③ When IGF-1R is activated, the following three signaling pathways are activated.

>> ○ STAT3

>> ○ PI3K → AKT (inhibited by PTE) → mTOR → S6K

>> ○ GRB2 → Ras / Raf → MEK → MAPK

> ④ IGF-1R promotes malignant tumors.

> ⑤ Inhibitors: AXL1717, linsitinib (currently in phase 3 trials)

⑻ **Example 5.** IR (insulin receptor)

> ① Structure

>> ○ Extracellular ligand-binding domain: Contains two α subunits.

>> ○ Transmembrane domain

>> ○ Cytoplasmic domain: Contains two β subunits.

>> ○ Total of 3 disulfide bonds: α-α, α-β, α-β

>> ○ β subunits function as tyrosine kinases.

> ② Experiment: In cancer cells like HepG2, both IGF-1R and IR are overexpressed, forming IGF-1R/IR heterodimers.

>> ○ IGF-1R homodimer: Can bind to ligands IGF-1 and IGF-2.

>> ○ IR homodimer: Can bind to ligands IGF-2 and insulin.

>> ○ IGF-1R/IR heterodimer: Can bind to ligands IGF-1, IGF-2, and insulin,

>> ○ IGF-1R/IR heterodimer has a broad ligand-binding site, making it sensitive to anticancer agents.

>> ○ Anti-IGF1R antibody can inhibit the proliferation of cancer cells dependent on IGF-1R/IR heterodimers.

 ⑼ **Example 6.** Bruton's tyrosine kinase: The drug ibrutinib targets this.

<br>

<br>

## **5. Serine/Threonine Kinase Receptors**

 ⑴ **Type 1.** TGF-β receptors

> ① 1<sup>st</sup>. The TGF-β1 ligand binds to the TGF-βRⅡ receptor, forming the TGF-βRⅠ complex.

> ② 2<sup>nd</sup>. The TGF-βRⅠ complex activates Smad2 and Smad3: This process is Inhibited by Smad7.

> ③ 3<sup>rd</sup>. Activated Smad2 and Smad3 act as transcription factors by binding Smad4.

> ④ Function: Involved in wound healing, angiogenesis, immune regulation, cancer development

<br>

<br>

## **6. Intracellular Receptors**

 ⑴ Overview

> ① Binding: Lipophilic ligands (e.g., steroid hormones)

> ② Location: Inside the cytoplasm.

> ③ Mechanism: Direct entry into the nucleus → Transcription factors

 ⑵ **Example 1.** PPAR (Peroxisome Proliferator-Activated Receptor)

> ① Structure: A/B domain (N-terminus) + C domain (an evolutionarily conserved DNA-binding domain) + E domain (hormone-binding C-terminus)

> ② **Type 1.** PPARα: Abundant in liver, skeletal muscle, kidney, heart, and blood vessels; low in fat and cartilage.

> ③ **Type 2.** PPARβ/δ: Expressed throughout the body, relatively high expression in brain, stomach, and colon.

> ④ **Type 3.** PPARγ: Expressed in mammalian adipose tissue, vascular smooth muscle, heart muscle. Important transcription factor regulating cell division.

 ⑶ **Example 2.** [Prostaglandin Receptor (PtgR)](https://jb243.github.io/pages/86)

> ① Prostaglandin: Causes inflammation (fever), mucous secretion, headaches, blood clotting, smooth muscle contraction (uterine contraction in females).

> ② Prostaglandin is produced in almost all cells and acts as a local regulator due to its unstable molecular structure.

> ③ Immune cells such as macrophages facilitate the transfer of prostaglandins into the cytoplasm of neighboring cells to induce an inflammatory response.

 ⑷ **Example 3.** [Estrogen Receptor](https://jb243.github.io/pages/553)(ER, estrogen receptor)

> ① [Lipophilic hormone](https://jb243.github.io/pages/89)

>> ○ Pathway: Binds to plasma transport proteins and moves to tissues → Intracellular receptor → Gene expression

>> ○ Synthesized and secreted as needed.

>> ○ Steroid hormones, thyroxine, nitric oxide (NO), adrenal cortex hormones

> ② Genetic Pathway: Estrogen binds to ERα or ERβ and acts on ERE or AP-1 within target DNA to activate transcription.

> ③ Non-genetic Pathway: Estrogen + ERα/ERβ or Estrogen + GPR30 activates signaling pathways involving MAPK and cAMP.

 ⑸ **Example 4.** [Granzyme](https://jb243.github.io/pages/86)

> ① A type of protease that enters infected cells through intracellular uptake.

> ② Induces apoptosis in target cells, cleaving nuclei and cytoplasm.

 ⑹ **Example 5.** cGAS-STING pathway

> ① 1<sup>st</sup>. dsDNA (double-stranded DNA) binds with the cGAS (cyclic GMP-AMP synthase) enzyme.

> ② 2<sup>nd</sup>. dsDNA-cGAS complex binds to cGMP.

>> ○ Binding is inhibited by ENPP1.

> ③ 3<sup>rd</sup>. dsDNA-cGAS-cGMP complex activates STING (stimulator of interferon gene).

>> ○ STING: Also known as TMEM173, MPYS/MITA/ERIS. Encoded by the STING1 gene.

> ④ 4<sup>th</sup>. Activated STING moves to the Golgi apparatus.

> ⑤ 5<sup>th</sup>. TBK1/IRF3, IKK-IκB signaling pathways are activated.

> ⑥ 6<sup>th</sup>. Ultimately IFN-β and IL-6 cytokines are released.

> ⑦ Function

>> ○ Innate immune response: Through this pathway, type I interferon is produced when a cell is infected by an intracellular pathogen.

>> ○ Prevents the spread of the infection source from the infected cell to neighboring cells.

<br>

<br>

## **7. Ion Channels**

 ⑴ Ligand-Gated Ion Channels

> ① Nicotinic Acetylcholine Receptor (nAhR): Also known as ionotropic acetylcholine receptor.

>> ○ Overview

>>> ○ Found in autonomic ganglia, neuromuscular junctions, central nervous system, etc.

>>> ○ Not present in sinoatrial node, cardiac muscle fibers,

>>> ○ Enables rapid neural transmission as an excitatory receptor.

>>> ○ Upon acetylcholine binding, both Na<sup>+</sup> and K<sup>+</sup> can pass through, with Na<sup>+</sup> permeability being greater, causing depolarization.

>>> ○ Named "nicotinic" due to its response to nicotine.

>> ○ Structure: Pentamer

>>> ○ Muscle-type: (α1)<sub>2</sub>β1δε or (α1)<sub>2</sub>β1δγ

>>> ○ Ganglion-type: (α3)<sub>2</sub>(β4)<sub>3</sub>

>>> ○ Heteromeric CNS-type: (α4)<sub>2</sub>(β2)<sub>3</sub>

>>> ○ Further CNS-type: (α3)<sub>2</sub>(β4)<sub>3</sub>

>>> ○ Homomeric CNS-type: (α7)<sub>5</sub>

>> ○ Types

>>> ○ N1 receptor: Located in neuromuscular junctions.

>>> ○ N2 receptor: Found in brain, dendrites, sympathetic nerves.

>> ○ Examples

>>> ○ Sodium channels involved in generating action potentials.

>>> ○ Acetylcholine receptors in [skeletal muscles](https://jb243.github.io/pages/88#2-model-of-skeletal-muscle-contraction).

>> ○ Inhibitors

>>> ○ Sarin, DIFP, and Tabun: Covalent inhibitors of acetylcholinesterase.

>>> ○ Curare: Blocks nicotinic receptors, acting as a skeletal muscle relaxant.

> ② Na<sup>+</sup> Channel

>> ○ Plant-derived tubocurarine: Acts as a substrate-dependent sodium channel inhibitor.

 ⑵ Voltage-Gated Ion Channels (e.g., Axons)

> ① Tetrodotoxin: Irreversible inhibitor of voltage-gated Na<sup>+</sup> channels.

> ② Tetraethylammonium: Blocks voltage-gated K<sup>+</sup> channels.

> ③ [Botulinum toxin](https://jb243.github.io/pages/1122): Blocks voltage-gated Ca<sup>2+</sup> channels at neuromuscular junctions → Inhibits acetylcholine release → Causes muscle paralysis.

 ⑶ Mechanosensitive Ion Channels

> ① [Auditory receptor](https://jb243.github.io/pages/1290)

> ② [Equilibrium (vestibular) receptor](https://jb243.github.io/pages/1291)

> ③ [Cutaneous sensory receptor](https://jb243.github.io/pages/1294)

<br>

<br>

## **8. Adhesion Receptors**

 ⑴ **Type 1.** [Integrin](https://jb243.github.io/pages/1409)

> ① 1<sup>st</sup>. Src, PYK2, FAK, SOS, GRB2, RACK1

> ② 2<sup>nd</sup>. Rac + GTP

> ③ 3<sup>rd</sup>. PAK

> ④ 4<sup>th</sup>. Raf1, MEK1

> ⑤ 5<sup>th</sup>. Erk1/2, MSK1/2

> ⑥ 6<sup>th</sup>. Fos, Ets, Elk, HIF1, STAT3, CREB, c-Jun

<br>

<br>

## **9. Other Receptors**

⑴ TNF receptors

> ① TNFR

>> ○ TNFR1: Associated with inflammation, apoptosis. 55 kDa

>> ○ TNFR2: Associated with anti-inflammatory response. 75 kDa

>> ○ In addition, receptors with similar structures that mediate inflammatory responses form the TNFR superfamily (e.g., Fas receptor).

> ② TNF (tumor necrosis factor)

>> ○ TNF-α: Exists in membrane-bound form (mTNF-α) and soluble form (sTNF-α) that dissolves in water.

>> ○ TNF-β

> ③ Cell death signaling pathway

>> ○ TNFR → TRADD → FADD → Caspase 8 → Caspase 3 → Apoptosis

>> ○ TNFR → TRADD → TRAF2 → clAPS → Apoptosis

>> ○ TNFR → TRADD → TRAF2 → MEKK1/4 → MEKK4/7 → JNK → Apoptosis

>> ○ 1<sup>st</sup>. Fas or TNF binds to receptors.

>> ○ 2<sup>nd</sup>. CASP8 (caspase 8) binds with an adaptor, forming DISC.

>> ○ 3<sup>rd</sup>. DISC activates caspase 3.

>> ○ 4<sup>th</sup>. CASP3 (caspase 3) causes cell death.

> ④ Cell survival and inflammatory response signaling pathway

>> ○ TNFR → TRAF2 → MEKK1/4 → MEKK4/7 → JNK → AP-1 → Inflammation and survival

>> ○ TNFR → TRAF2 → ASK1 → MEKK4/7 → JNK → AP-1 → Inflammation and survival

>> ○ TNFR → TRAF2 → RIP → MEKK3/6 → MAPK → Inflammation and survival

>> ○ TNFR → TRAF2 → NIK → IKK → NF-κB → Inflammation and survival

>> ○ TNFR → TRAF2 → RIP → IKK → NF-κB → Inflammation and survival

 ⑵ [Toll-like receptor](https://jb243.github.io/pages/86)(TLR)

> ① Types of TLRs

>> ○ [TLR-1](https://en.wikipedia.org/wiki/TLR_1): Recognizes multiple triacyl lipopeptide.

>> ○ [TLR-2](https://en.wikipedia.org/wiki/TLR2): Recognizes lipoteichoic acid. Activates innate immunity.

>> ○ [TLR-3](https://en.wikipedia.org/wiki/TLR3): Recognizes dsRNA present in viruses.

>> ○ [TLR-4](https://en.wikipedia.org/wiki/TLR4): Recognizes LPS (lipopolysaccharide) present in Gram-negative bacteria

>> ○ [TLR-5](https://en.wikipedia.org/wiki/TLR5): Recognizes flagellin, the structural subunit of prokaryotic flagella.

>> ○ [TLR-6](https://en.wikipedia.org/wiki/TLR6): Recognizes multiple diacyl lipopeptide.

>> ○ [TLR-7](https://en.wikipedia.org/wiki/TLR7): Recognizes single-stranded RNA.

>> ○ [TLR-8](https://en.wikipedia.org/wiki/TLR8): Recognizes small synthetic compounds and single-stranded RNA.

>> ○ [TLR-9](https://en.wikipedia.org/wiki/TLR9): Recognizes unmethylated C<sup>p</sup>G DNA sequences and oligodeoxynucleotide DNA.

> ② **Pathway 1.** MyD88-dependent pathway

>> ○ Overview: Mechanism pathway via signal transduction. Activates NF-κB. Increases TNF-α and IL-1β.

>> ○ TLR → MyD88 → TRAF6 → NF-κB → NF-κB translocates into the nucleus.

>> ○ TLR → MyD88 → TRAF6 → MAPK → AP-1

> ③ **Pathway 2.** TRIF-dependent pathway

>> ○ Overview: Mechanism pathway via endosome.

>> ○ TLR → TAM, TRIF → IRF3 → IRF3 translocates into the nucleus → Type I IFN

>> ○ TLR → TAM, TRIF → TRAF6 → NF-κB → NF-κB translocates into the nucleus.

>> ○ TLR → TAM, TRIF → TRAF6 → MAPK → AP-1

⑶ Notch signaling

> ① Function: Determines cell fate, and involved in cell division, cell differentiation, cell death, etc.

> ② Mammals have four types of Notch receptors: NOTCH1, NOTCH2, NOTCH3, NOTCH4.

 ⑷ Wnt signaling: Associated with Frizzled receptor.

 ⑸ Morphogen

> ① Hh((Hedgehog) is involved in the patterning of cells located within 30 μm in Drosophila.

> ② Shh(Sonic Hedgehog) is involved in the patterning of cells located within 100 μm in mice.

>> ○ The term is derived from the video game Sonic the Hedgehog.

> ③ Ihh(Indian Hedgehog) is involved in the patterning of cells located within 300 μm in mice.

> ④ PRHrP

> ⑤ GDF5

> ⑥ BMP

> ⑦ WNT

 ⑹ Enzyme-coupled receptor

> ① **Case 1.** When the receptor itself has a catalytic domain.

> ② **Case 2.** When a coenzyme assists.

> ③ In both cases, dimerization of the ECR is induced, triggering signal transduction.

⑺ AGE-RAGE

⑻ Rap1

⑼ NOD-like receptor

⑽ YAP/TAZ signaling

> ① TAZ signaling activates fibrosis and necroptosis.

⑾ Hippo signaling

⑿ FGFR pathway

⒀ E-cadherin-integrin pathway

⒁ Gene summary related to signal transmission

> ① nuclear hormone receptor: NHR 

> ② Jak-Stat: STAT

> ③ Wnt: TCF/Lef

> ④ Hedgehog: Gli 

> ⑤ TGF-β/BMP: Smad

> ⑥ MAPK: ETS

> ⑦ Notch: CSL

<br>

<br>

## **10. Signal Transduction Enhancers**

⑴ AMPK: A769662

<br>

<br>

## **11. Signal Transduction Inhibitors**

⑴ mTORC1 inhibitor: Rapamycin (Sirolimus)

⑵ MEK1/2 inhibitor: Trametinib (Mekinist), Cobimetinib, Refametinib

⑶ ERK1/2 inhibitor: MK-8353, SCH772984

⑷ AKT1/2 inhibitor: MK-2206

⑸ MAPK9 inhibitor: AS602801

⑹ PI3K inhibitor: LY294002, Taselisib, Alpelisib, MK-2206, Idelalisib (CAL-101), Dactolisib (BEZ-235), Everolimus, Pictilisib (GDC-0941), Apitolisib (GDC-0980)

⑺ IκB inhibitor: Bortezomib

⑻ sPLA2-IIa inhibitor: cFLSYR, c(2NapA)LS(2NapA)R

⑼ AMPK inhibitor: Dorsomorphin

⑽ Phosphorylation signal transduction inhibitors: Lapatinib

⑾ PARP1/2 inhibitor: Olaparib

⑿ PLK4 inhibitor: CFI400945

⒀ p38 inhibitor: VX-745

⒁ CHEK1/2 inhibitor: AZD-7762

> ① CHEK1-selective inhibitor: SAR-020106, Rabusertib

> ② CHEK2-selective inhibitor: CCT-241533

⒂ BRAF inhibitor: Dabrafenib, Vemurafenib (Zelboraf), PLX4720

⒃ JNK inhibitor: JNK-IN-8

⒄ WEE1, PLK1 inhibitor: MK-1775

⒅ BCL2, BCL-XL, BCL-W inhibitor: Navitoclax

⒆ TGF-βR inhibitor: RepSox

⒇ Tyrosine phosphorylase inhibitors: Imatinib (Glivec), Dasatinib (Sprycel), Sunitinib (Sutent), Nilotinib (Tasigna), Sorafenib (Nexavr), Temsirolimus (Torisel)

<br>

---

_Input: 2021.01.24 23:48_

_Modified: 2022.06.13 14:05_




